Why the study?
Debate persists regarding whether the known association between race and blood pressure control is explained solely by unadjusted socioeconomic variables or by genetic variation.
Is genetic ancestry associated with resistant hypertension in Brazilian patients with stage II hypertension?
Is genetic ancestry associated with resistant hypertension in Brazilian patients with stage II hypertension?
Increased African genetic ancestry was not significantly associated with resistant hypertension in a Brazilian cohort, suggesting that socioeconomic factors may play a larger role in blood pressure control disparities.
Answers are grounded in this paper and cite their sources.
Genetic ancestry not associated with resistant hypertension; leaves open socioeconomic factors as primary drivers of racial BP disparities.
Resistant hypertension (RH) is defined as uncontrolled blood pressure despite treatment with three or more antihypertensive medications, including, if tolerated, a diuretic in adequate doses. It has been widely known that race is associated with blood pressure control. However, intense debate persists as to whether this is solely explained by unadjusted socioeconomical variables or genetic variation. In this scenario, the main aim was to evaluate the association between genetic ancestry and resistant hypertension in a large sample from a multicenter trial of stage II hypertension, the ReHOT study. Samples from 1,358 patients were analyzed, of which 167 were defined as resistant hypertensive. Genetic ancestry was defined using a panel of 192 polymorphic markers. The genetic ancestry was similar in resistant (52.0% European, 36.7% African and 11.3% Amerindian) and nonresistant hypertensive patients (54.0% European, 34.4% African and 11.6% Amerindian) (p > 0.05). However, we observed a statistically suggestive association of African ancestry with resistant hypertension in brown patient group. In conclusion, increased African genetic ancestry was not associated with RH in Brazilian patients from a prospective randomized hypertension clinical trial.
No takes yet. Share an insight, caveat, or question.
Bueno et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: